At present, the therapeutic approach primarily involves the use of SGLT2 inhibitors, coupled with rigorous management of the risk factors, such as hypertension, diabetes, hyperlipidemia, and weight control [26]. This evidence concerns the gene SLC5A2 and Hypertension.